06/07/2015 23:21:54 Cookie Policy Free Membership Login

Allergy Thera. Share Chat - AGY

Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change Price Change % Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.25 +1.06% 23.75 23.00 24.50 23.75 23.75 23.75 98,476 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 42.0 1.1 0.2 148.4 129.64

Allergy Therapeutics Share Discussion Threads

Showing 3025 to 3050 of 3050 messages
Chat Pages: 122  121  120  119  118  117  116  115  114  113  112  111  >>
DateSubjectAuthorDiscuss
06/7/2015
16:00
Proactive video with Murray Skinner, director of quality & science at Allergy http://tinyurl.com/plm6ryrftseproactive
06/7/2015
08:50
Proactive investors articleon todays excellent news. Worth visiting the page for a picture of the dust mite alone. Science fiction stuff! http://www.proactiveinvestors.co.uk/companies/news/108697/allergy-therapeutics-reveals-positive-results-from-dust-mite-study-108697.html?utm_source=twitterfeed&utm_medium=twitter Allergy Therapeutics reveals positive results from dust mite study 07:38 06 Jul 2015 Share Not the sort of thing you want to see while eating your cornflakes. But 20% of the population is allergic to house dust mites. 07:38 Ian Lyall (mailto:ian.lyall@proactiveinvestors.com) The one-year follow-up assessment of Acarovac Plus was carried out by Dr Albert Roger, of the Universitari Hospital Germans Trias Pujol, Badalona, Spain. It looked at the the safety, tolerability and long-term effectiveness of the injections. Dr Roger and his team found Acarovac Plus saw a greater than 50% decrease in symptom scores in the 30 patients who took part in the study. “[The] therapy not only led to a high rate of patient satisfaction early in treatment, but also the convenient maintenance regime of injections every six weeks has the potential to improve the adherence and compliance with the vaccine regime that is essential for a successful treatment," the researcher said. On the back of these promising results, Allergy Therapeutics http://www.proactiveinvestors.co.uk/LON:AGY/Allergy-Therapeutics/) has begun developing an ultra-short course dust mite treatment called Acarovac Quattro. It will sit in the company’s medicine chest of products alongside Pollinex Quattro for hay fever. Chief executive Manuel Llobet said: “We expect that Acarovac Quattro will have all the benefits of both Pollinex Quattro technology platform coupled with the efficacy seen with Acarovac Plus. “Over 20% of the population in both Europe and the US have an allergic reaction to house dust mites and so an effective short course allergy vaccine will be an important and potentially valuable addition to our product range."qackers
06/7/2015
08:12
Allergy Therapeutics PLC Positive Dust Mite Study Results Share On Facebook Print Alert TIDMAGY Allergy Therapeutics PLC 06 July 2015 6 July 2015 Allergy Therapeutics plc ("Allergy Therapeutics" or "the Company") Positive Dust Mite Study Results Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces positive results from its prospective observational Acarovac Plus clinical study for the treatment of house dust mite allergy. Acarovac Plus is being developed as one of the Company's new generation of products to address the perennial allergy market with innovative and short-course therapies. At the Adjuvants in Allergy conference over the past weekend, Dr. Albert Roger, Director of the Allergy Unit at Universitari Hospital Germans Trias Pujol, Badalona Spain, presented the results of a prospective observational one-year follow-up study, comparing the safety, tolerability and long-term effectiveness of Acarovac Plus using Dermatophagoides pteronyssinus (house dust mite) in 30 adult patients with allergic rhinitis and/or asthma. Acarovac Plus has been designed to administer maintenance doses every 6-8 weeks, reducing the number of annual injections required and providing a natural, biodegradable, alternative depot(1) vaccine. Tolerability of Acarovac Plus was demonstrated with no reported adverse events. The effectiveness of Acarovac Plus was measured in patients using a nasal provocation test, which evaluates the sensitivity of each patient to mite allergens. Nasal airway assessments were performed using peak nasal inspiratory flow measurements. In summary, a reduction in symptom scores of >50% were observed during follow up visits after one year. Immunological markers were also assessed and showed significant improvements in antibody IgG4 and anti-inflammatory IL-10 molecules, indicating tolerance induction in patients after one year of treatment. A validated patient satisfaction survey provided information that was reflective of the clinical findings from the study. A high degree of overall patient satisfaction was observed, which encompassed significant improvements in scores after one year in relation to overall effectiveness and convenience of the treatment. This reinforces one of the main objectives of Allergy Therapeutics in improving patient life by producing effective treatments, while at the same time reducing the discomfort of injections, improving compliance and adherence of allergy immunotherapy products. Further to the efficacy noted for Acarovac Plus(2) , Allergy Therapeutics is developing Acarovac Quattro, an ultra-short course therapy utilising the adjuvant monophosphoryl lipid A (MPL), which is used in the Company's successful Pollinex Quattro product range currently in late stage development in Europe and the US. Dr Roger, principal investigator for the study, said: "The successful clinical results in the one year follow-up study clearly demonstrate the effective treatment of house dust mite allergy by Acarovac Plus. We also observed significant decreases in symptom scores and improvement in nasal sensitivity immediately after the up dosing phase of one month. Acarovac Plus therapy not only led to a high rate of patient satisfaction early in treatment, but also the convenient maintenance regime of injections every 6 weeks has the potential to improve the adherence and compliance with the vaccine regime that is essential for a successful treatment." Manuel Llobet, Chief Executive Officer, commented: "Following the continued successful development of the Pollinex Quattro product range addressing the seasonal segment of the allergy market, we now intend to extend this innovative franchise into developing perennial allergy vaccines. On the back of these promising results for Acarovac Plus in ameliorating the symptoms of house dust mite allergy, we have embarked on the development of an ultra-short course version utilising the adjuvant MPL. We expect that Acarovac Quattro will have all the benefits of both Pollinex Quattro technology platform coupled with the efficacy seen with Acarovac Plus. Over 20% of the population in both Europe and the US have an allergic reaction to house dust mites and so an effective short course allergy vaccine will be an important and potentially valuable addition to our product range"jimmyloser
06/7/2015
07:28
More good news. May be the only blue on my screen today amongst the see of red!audigger
02/7/2015
08:40
 2 July 2015 Allergy Therapeutics plc ("Allergy Therapeutics" or "the Company") Company to Host Key Allergy Conference Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces that it is hosting the Eighth Annual Adjuvants in Allergy Conference in Amsterdam on the 2-4 July. At the conference, Dr. Albert Roger Director of the Allergy Unit at Universitari Hospital Germans Trias Pujol, Badalona Spain, will present data from the Company's recent Acarovac efficacy study for the treatment against house dust mite allergy. Acarovac has been Allergy Therapeutics strongest growing treatment in Spain this year and it is one of the Company's new generation of products developed to address the perennial allergy market with innovative and short-course therapies. The conference provides an outstanding opportunity for scientific debate and dialogue amongst 200 specialists in respiratory diseases and allergology from all over Europe and America. New perspectives and innovations in allergy treatment will be presented by international key opinion leaders in order to initiate the process of global shared knowledge in these areas and ultimately lead to improvements in patient outcomes. There is an exciting programme of topics to facilitate in-depth discussions, which include, the impact for allergists on changes to the climate and migration patterns, the distribution of pollen counts and their annual patterns, the generation and maintenance of allergen specific T-cell tolerance, options and strategies for primary and secondary prevention of atopy and asthma, and the dramatic increase in the prevalence of allergic diseases. Manuel Llobet, Chief Executive Officer, commented: "Allergy Therapeutics is proud to host the Eighth Annual Adjuvants in Allergy Conference, a highly scientific open forum to discuss allergy topics with expert key opinion leaders and allergists from around the world. The aim of the conference is to encourage the medical community to consider innovative solutions for patients suffering from allergies and we are excited to be at the forefront of these discussions."jimmyloser
02/7/2015
07:53
Yep, I tend to agree with you. I still have this down for September 2017 before we see the real excitement. Looks like we may have an early doors step in the right direction!!jimmyloser
02/7/2015
07:24
Nowt wrong with a bit of exposure either; always good to see a company engaging in the underlying science. We may see 30p by end of July especially if Greece sorts itself out and there is a general market bounce back.audigger
01/7/2015
22:34
September is my target time for that. Providing that..........?jimmyloser
01/7/2015
22:10
Looking like it's trying to breakout to 30p.....audigger
26/6/2015
12:41
Nice positive write up from Proactive investors. See note at end of article. Panmure Gordon looking for 33p http://www.proactiveinvestors.co.uk/news/details/108400/allergy-therapeutics-momentum-renewed-with-us-programme-kick-start-108400.html?utm_source=Sign-Up.to&utm_medium=email&utm_campaign=7163-336278-Proactivity+-+25%2F06%2F2015 Allergy Therapeutics’ momentum renewed with US programme kick-start Share 13:29 25 Jun 2015 Allergy Therapeutics has renewed momentum - as its announcement this morning showing a kick-start to its US growth ambitions aptly demonstrated. "We've really de-risked the proposal from the one we outlined in the fundraising," finance director Ian Postlethwaite told Proactive. Allergy Therapeutics (LON:AGY) has renewed momentum - as its announcement this morning showing a kick-start to its US growth ambitions aptly demonstrated. Following what it called "productive" talks with the all important US Food and Drug Administration (FDA), the pharma group is to resume its clinical programme of grass allergy product Pollinex Quattro in a bid to take it through to a market launch in 2019. It is a milestone, not least as it draws a line firmly under past problems with the pipeline. In 2007, the FDA put a stop to the development of Pollinex after one patient had an adverse reaction to the grass allergy injection. Those familiar with the story will know the firm now has the financial wherewithal to start this process again and to advance the development pipeline, having raised £20mln via a placing in March this year. "We've really de-risked the proposal from the one we outlined in the fundraising," finance director Ian Postlethwaite told Proactive. It now sets in train clinical trials, scheduled to start in September this year, with contract research organisation Inflamax set to run the studies, which represents a further de-risking. Postlethwaite is optimistic that the product will hit the US markets at the right time, when the market may be more receptive to a European type model. The firm is already an established provider of allergy vaccines in Europe but this will mark its first foray into the US. Currently, the market across the pond is very different in that manufacturers sell bulk products to individual US allergists, which then make up their own products. But there is a shift now taking place, as Postlethwaite explained, as evidenced by a couple of European players recently having vaccines registered in the US. Allergy has already spent U$100mln on the Pollinex programmes and also in the pipeline are similar treatments for ragweed and tree pollen. Unlike grass, these are not funded, but Postlethwaite notes that only a phase III trial is still required for ragweed and a phase II for the tree candidate. One option he says is available to the company would be to out-license these products - a growing trend in the pharma world. It is worth noting that Allergy, via its core European business, is cash generative. It recently funded the purchase of Spanish vaccine specialist Alerpharma from its own coffers. The interim results revealed the group posted double digit revenue growth, due to increased market share, bringing it to just over £30mln and an operating profit of £7.5mln, up 13% on the year earlier. On the balance sheet, the group improved the cash position to £8mln compared to £5.2mln in the first half of 2014. Panmure Gordon in a note following the results in March issued a target price of 33p and gave an upbeat assessment of prospects. “The company continues to take market share from its competitors and despite exchange rate head winds, the business is taking advantage of its product differentiation,” analyst Savvas Neophytou said in the note. Shares added 4.24% to 21.50p today.qackers
26/6/2015
09:06
It is truly nice to see confidence gaining in the AGY managements strategy, it was obviously evident when they raised £22million+ They just do not put a foot wrong in my eyes nor can they! Go for it AGY!jimmyloser
25/6/2015
07:58
At last the news we have been waiting for. Not sure what response we'll see in the SP today, but rest assured if these trials are successful then we're looking at several multiples of where we are now. I guess it depends how many people will invest based on US income potential as opposed to waiting until actual income. That said, lets not forget the Co is already profitable based on its Eu business which is growing.....audigger
25/6/2015
07:05
FANTASTIC Thank you AGYjimmyloser
06/6/2015
21:59
I too am puzzled. A few nuggets in there I thoughtIn addition to progressing our USA etc. progressingImmediately earnings enhancingState of the art manufacturing Etcjimmyloser
05/6/2015
11:53
Interesting! Strange that the SP hasn't moved in response to this news....audigger
01/5/2015
08:14
That appears to be that 600k overhang gone! impo.jimmyloser
15/4/2015
17:15
Could well be buys. Not much volume at the moment.Just sold my Persimmon holding today (nice eaner that was!) so may well top-up on these.....just trying to get the timing right, which usually I don't!audigger
15/4/2015
15:15
AuDigger It looks like sells at 19.65p now and buys at 20.3p Lots of nibble type buys going through Do you agree?jimmyloser
14/4/2015
08:53
Seems to have been a lot of low volume selling over the last week. Looks like its been walked down prior to what we hope is good news on the Phase III trial.audigger
09/4/2015
13:23
They did say that and I would expect an RNS as its key news. May be FDA are dragging their heels, not unknown!audigger
09/4/2015
07:52
AuDigger Didn't they indicate that they expected clearance for the trials from the FDA in mid March? Do you feel that they would have to RNS that news? jljimmyloser
09/4/2015
07:37
All good stuff. Invesco almost doubled thier holding. Looking like the new placing has found several good homes. Is it time for the crawl back up to 30p?audigger
09/4/2015
07:37
All good stuff. Invesco almost doubled thier holding. Looking like the new placing has found several good homes. Is it time for the crawl back up to 30p?audigger
07/4/2015
15:15
Good post and appreciated.jimmyloser
Chat Pages: 122  121  120  119  118  117  116  115  114  113  112  111  >>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 150706 23:21